IMarkHD: in Vivo Longitudinal Imaging of HD Pathology
Longitudinal Adaptive Study of Molecular Pathology and Neuronal Networks in Huntington's Disease Gene-Expansion Carriers (HDGEC) and Healthy Controls Using Positron Emission Tomography (PET) and Multi-modal Magnetic Resonance Imaging (MRI)
Sponsor: CHDI Foundation, Inc.
A observational or N/A phase clinical study on Huntington Disease, this trial is actively recruiting participants. The trial is conducted by CHDI Foundation, Inc. and has accumulated 13 data snapshots since 2021. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
13 versions recorded-
Apr 2025 — Present [monthly]
Recruiting
-
Sep 2024 — Apr 2025 [monthly]
Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Recruiting
-
Nov 2023 — Jul 2024 [monthly]
Recruiting
-
Nov 2022 — Nov 2023 [monthly]
Recruiting
Status: Not Yet Recruiting → Recruiting
▶ Show 8 earlier versions
-
Dec 2021 — Nov 2022 [monthly]
Not Yet Recruiting
-
Jan 2021 — Dec 2021 [monthly]
Not Yet Recruiting
-
Nov 2020 — Jan 2021 [monthly]
Not Yet Recruiting
-
Oct 2018 — Nov 2020 [monthly]
Not Yet Recruiting
-
Jun 2018 — Oct 2018 [monthly]
Not Yet Recruiting
-
May 2018 — Jun 2018 [monthly]
Not Yet Recruiting
-
Apr 2018 — May 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- CHDI Foundation, Inc.
- King's College London
For direct contact, visit the study record on ClinicalTrials.gov .